Skip to main content

Table 3 Description of PIs with a major clinical impact (n = 21)

From: Clinical, economic and organizational impact of pharmacist interventions on injectable antineoplastic prescriptions: a prospective observational study

UnitDRPDrug(s)PIDescriptionEconomic impactOrganizational impact
Hepato-gastro enterology day care unitNon conformity to guidelinesPanitumumabDrug switchCourse number 1: Prescription VECTIBIX / FOLFOX instead of AVASTIN FOLFOX (RAS analysis in progress)10
Hepato-gastro enterology day care unitNon conformity to guidelinesPanitumumabDrug switchCourse number 1: Prescription VECTIBIX / FOLFOX instead of AVASTIN FOLFOX (RAS analysis in progress)10
Oncology day care unitNon conformity to guidelinesGemcitabineDrug discontinuationPrescription signed and green light given for gemcitabine but course should be canceled due to thrombocytopenia11
Radiotherapy day care unitNon conformity to guidelinesCisplatinDose adjustmentOverdose: Prescription cisplatin 60 mg / m2 for 2 days, while the patient should not receive cisplatin on day 211
Pneumology day care unitContra indicationCisplatinDrug discontinuationPrescription of an adjuvant cisplatin course for a patient having a clearance of creatinine 43 ml/min according to the CKD EPI formula11
Oncology day care unitUntreated indicationTrastuzumabAddition of a new drugError in the protocol: missing one line in protocol on Taxotere Cyclophosphamide Trastuzumab01
Oncology day care unitUntreated indicationTrastuzumabAddition of a new drugError in the protocol: missing one line in protocol on Taxotere Cyclophosphamide Trastuzumab01
Hepato-gastro enterology day care unitSupra-therapeutic dosageFluorouracile
Oxaliplatin
Dose adjustmentReductions of 50% of in 5 fluorouracil (5FU) and of 80% in oxaliplatin omitted in a patient with toxic
ileitis to 5 FU in his medical records
10
Oncology day care unitSupra-therapeutic dosageCetuximabDose adjustmentExpected reduction cetuximab 200 mg / m2 instead of 500 mg / m2 not appliedToxicity during previous treatments: folliculitis, xerosis11
Oncology day care unitSupra-therapeutic dosageCyclophosphamide
Doxorubicine
Cisplatine
Dose adjustmentExpected reductions of 80% for Cyclophosphamide and doxorubicin and of 66% for cisplatin omitted. During the intercure period: anemia, thrombocytopenia, non-febrile agranulocytosis, oedematous decompensation leading to emergency consultation11
Oncology day care unitSupra-therapeutic dosageIrinotecanDose adjustmentReduction of 80% for irinotecan omitted
During the intercure period: Hospitalization for diarrhea during previous course
11
Oncology day care unitSupra-therapeutic dosagePaclitaxelDose adjustmentExpected reduction to 80% paclitaxel not appliedToxicity: paresthesia of hands and feet prior to paclitaxel11
Oncology day care unitSupra-therapeutic dosageCabazitaxelDose adjustmentExpected reduction to 80% for carbazitaxel
Hospitalization during previous course for deterioration in general condition and nausea
11
Oncology day care unitSupra-therapeutic dosagePaclitaxelDose adjustmentExpected reduction of 80% for paclitaxel omitted
Toxicity: Feet paresthesia prior to paclitaxel
11
Oncology day care unitSupra-therapeutic dosagePaclitaxelDose adjustmentExpected reduction of 80% paclitaxel not appliedToxicity: Hands and feet paresthesia prior to paclitaxel11
Oncology day care unitSupra-therapeutic dosagePaclitaxelDose adjustmentExpected reduction of 80% for paclitaxel not applied
Toxicity during previous treatments: Neuropathy
11
Oncology day care unitSupra-therapeutic dosageDocetaxelDose adjustmentExpected reduction of 66% for not applied
Toxicity during intercure: Edema of the lower limbs
11
Oncology day care unitSupra-therapeutic dosageVinorelbineDose adjustmentPrescription of weekly navelbine at dosage of 25 mg / m2Medical history: Neutropenia grade IV with a weekly navelbine protocol11
Oncology day care unitSupra-therapeutic dosageVinorelbineDose adjustmentExpected reduction of 80% for navelbine
Toxicity during intercure: Hospitalization for general condition alteration and febrile peak
11
Oncology day care unitSupra-therapeutic dosageGemcitabineDose adjustmentExpected reduction of 80% for gemcitabine not applied
Toxicity during previous treatment: Febrile neutropenia
11
Oncology day care unitSupra-therapeutic dosageCisplatin
Fluorouracile
Dose adjustmentCourse number 1: expected reductions because of asthenia and undernutrition by 80% for cisplatin and fluorouracile not applied11
\